Thrombosis genetics in African Americans
非裔美国人的血栓形成遗传学
基本信息
- 批准号:9912811
- 负责人:
- 金额:$ 74.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-04-20 至 2023-03-31
- 项目状态:已结题
- 来源:
- 关键词:African AmericanAmericanAnticoagulantsAtherosclerosisBioinformaticsBiologicalBiological MarkersBiologyBloodBlood VesselsBlood coagulationCD14 geneCardiovascular DiseasesCause of DeathClinicalCoagulation ProcessCodeComplement Factor DComplexDataData SetDiseaseDisease OutcomeEnvironmental Risk FactorEthnic OriginEthnic groupEuropeanEventFactor VIIIFactor VIIaFactor XIIFactor XIaFibrin fragment DFibrinogenFibrinolytic AgentsGenerationsGeneticGenetic studyGenomicsHealthHemorrhageHemostatic functionHeritabilityInflammationInflammatoryInterleukin 2 ReceptorIschemic StrokeJackson Heart StudyKnowledgeLaboratoriesMeasurementMeasuresMediationMinorityModalityMulti-Ethnic Study of AtherosclerosisMyocardial InfarctionNational Heart, Lung, and Blood InstituteParticipantPathway interactionsPhenotypePlasmaPopulationPopulation GeneticsPredispositionRaceReasons for Geographic And Racial Differences in StrokeRiskRisk FactorsRoleSafetySample SizeSamplingSignal TransductionStrokeSystemTherapeuticThrombinThromboplastinThrombosisThrombusTrans-Omics for Precision MedicineUnited StatesUntranslated RNAValidationVariantVenousVenous Thrombosisatherosclerotic plaque rupturebasecardiovascular disorder riskcardiovascular healthcarotid intima-media thicknesscohortcoronary artery calcificationdatabase of Genotypes and Phenotypesepidemiology studyethnic disparitygamma Fibrinogengenetic approachgenetic associationgenetic variantgenome wide association studygenome-widegenomic locushealth disparityin vivoinnovationinterestnovelnovel markernovel strategiesracial disparityrare variantrisk variantthrombogenesisvascular inflammationwhole genome
项目摘要
ABSTRACT
Cardiovascular diseases are the leading cause of death in the United States, and
disproportionate rates are seen in minority African American populations. Thrombosis and
vascular inflammation are important contributors to atherosclerotic plaque rupture and vascular
occlusion that underlie myocardial infarction, ischemic stroke, as well as venous
thromboembolic disease. The identification of novel biomarkers and their assessment in
different ethnic populations can augment the information obtained from traditional CVD risk
factors as well as illuminate underlying disease mechanisms and health disparities. While blood
biomarkers have been shown to be critically important in the study of CVD, there is a deficit of
studies of these measures in African American populations. Preliminary data suggest that
thrombin generation, as quantified ex vivo by plasma measurement of endogenous thrombin
potential (ETP) is a novel approach to understanding the connection of both the intrinsic and
extrinsic coagulation pathways to thrombus formation in vivo. Whole genome sequence (WGS)
data, including both coding and functional noncoding variants, are required to identify the full
spectrum of contributions of rare variants to common diseases. WGS data are particularly
important among non-European ancestry groups, where there is still relatively limited genomic
information. Using stored baseline Jackson Heart Study (JHS) plasma samples from 3,500
African Americans, we propose to measure several emerging thrombosis and inflammation
plasma biomarkers (endogenous thrombin potential, fibrinogen gamma', coagulation factors VIII
and VIIa, soluble interleukin-2 receptor, soluble CD14, and soluble CD163) that are likely to
reflect and/or account for increased thrombogenicity and therefore may contribute to higher
rates of CVD in African Americans. We will assess the association of thrombosis biomarkers
and biomarker-associated genetic variants with more complex subclinical and clinical CVD
endpoints available in JHS and other African American cohorts, including REGARDS. By adding
these key measures of thrombosis and inflammation to the JHS and REGARDS data sets,
utilizing existing whole genome sequence data available through the NHLBI TOPMed project,
and using innovative analytical and population genetic approaches, we will be able to greatly
expand our knowledge of the role of thrombosis and inflammation in CVD health disparities.
抽象的
心血管疾病是美国死亡的主要原因,
在少数非洲裔美国人口中,观察到不成比例的率。血栓形成和
血管炎症是动脉粥样硬化斑块破裂和血管的重要因素
闭塞心肌梗死,缺血性中风和静脉
血栓栓塞疾病。鉴定新型生物标志物及其评估
不同的民族人口可以增加从传统CVD风险获得的信息
因素以及阐明潜在的疾病机制和健康差异。同时鲜血
生物标志物已被证明在CVD研究中至关重要,存在缺陷
对非裔美国人人口的这些措施的研究。初步数据表明
凝血酶的产生,通过血浆测量内源性凝血酶的血浆测量
势(ETP)是一种理解内在和固有联系的新方法
在体内形成血栓形成的外部凝血途径。整个基因组序列(WGS)
需要数据,包括编码和功能非编码变体,以确定完整
稀有变体对常见疾病的贡献范围。 WGS数据特别是
在非欧洲血统群体中,基因组仍然相对有限
信息。使用存储的基线杰克逊心脏研究(JHS)等离子体样品的3500
非裔美国人,我们建议测量几种新兴的血栓形成和炎症
等离子体生物标志物(内源性凝血酶电位,纤维蛋白原γ',凝血因子VIII
和VIIA,可溶性白介素-2受体,可溶性CD14和可溶性CD163)
反映和/或说明血栓形成性的增加,因此可能有助于更高
非洲裔美国人的CVD率。我们将评估血栓形成生物标志物的关联
以及具有更复杂亚临床和临床CVD的生物标志物相关遗传变异
JHS和其他非裔美国人队列中可用的终点,包括问候。通过添加
这些对JHS的血栓形成和炎症的关键衡量标准,并确定数据集,
利用通过NHLBI顶部项目获得的现有整个基因组序列数据,
并使用创新的分析和人口遗传方法,我们将能够极大地
扩展我们对血栓形成和炎症在CVD健康差异中的作用的了解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Leslie A Lange其他文献
Leslie A Lange的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Leslie A Lange', 18)}}的其他基金
相似海外基金
Cardiovascular risk from comprehensive evaluation of the CT calcium score exam
CT钙评分检查综合评估心血管风险
- 批准号:
10667803 - 财政年份:2023
- 资助金额:
$ 74.42万 - 项目类别:
Contact Pathway Inhibitor to Prevent Vascular Access Failure
接触途径抑制剂以防止血管通路失败
- 批准号:
10604057 - 财政年份:2023
- 资助金额:
$ 74.42万 - 项目类别:
Inhibitors of Human Factor XIIIa as New Anticoagulants
人类因子 XIIIa 抑制剂作为新型抗凝剂
- 批准号:
10629057 - 财政年份:2023
- 资助金额:
$ 74.42万 - 项目类别:
Leveraging the Microbiome, Local Admixture, and Machine Learning to Optimize Anticoagulant Pharmacogenomics in Medically Underserved Patients
利用微生物组、局部混合物和机器学习来优化医疗服务不足的患者的抗凝药物基因组学
- 批准号:
10656719 - 财政年份:2022
- 资助金额:
$ 74.42万 - 项目类别:
Ethnicity-determined T cell responses and GARP/TGFbeta1 signaling in prostate cancer
前列腺癌中种族决定的 T 细胞反应和 GARP/TGFbeta1 信号传导
- 批准号:
10358338 - 财政年份:2021
- 资助金额:
$ 74.42万 - 项目类别: